Core Viewpoint - The announcement highlights that Zhifei Biological's subsidiary, Zhifei Longkema, has received the clinical trial application acceptance notice from the National Medical Products Administration for its recombinant herpes zoster vaccine ZFA01, which utilizes a novel adjuvant to enhance immune responses [1] Company Summary - Zhifei Biological's subsidiary, Zhifei Longkema, is developing the recombinant herpes zoster vaccine ZFA01 [1] - The vaccine is designed to prevent diseases caused by herpes zoster infection [1] - The new adjuvant developed by the company aims to stimulate both cellular and humoral immune responses, potentially improving the vaccine's protective efficacy [1] Industry Summary - The vaccine development is part of the broader pharmaceutical industry efforts to enhance vaccine effectiveness through innovative adjuvants [1] - The acceptance of the clinical trial application indicates progress in the regulatory pathway for new vaccine candidates in the market [1]